 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| MK-6194 / Merck (MSD)
Trial termination: A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) (clinicaltrials.gov) - Aug 18, 2025
P2, N=169, Terminated, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Terminated; Business Reasons
- | MK-6194 / Merck (MSD)
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) (clinicaltrials.gov) - Aug 7, 2025
P2, N=149, Terminated, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Terminated; Business Reasons N=270 --> 149 | Trial completion date: Mar 2028 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jul 2025; Business Reasons
- || MK-6194 / Merck (MSD)
Trial completion date, Trial primary completion date: Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) (clinicaltrials.gov) - Apr 7, 2025
P2, N=270, Recruiting, Sponsor: Merck Sharp & Dohme LLC
N=270 --> 149 | Trial completion date: Mar 2028 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jul 2025; Business Reasons Trial completion date: Jul 2028 --> Mar 2028 | Trial primary completion date: Apr 2027 --> Nov 2026
- || MK-6194 / Merck (MSD)
Clinical, PK/PD data, Journal: Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. (Pubmed Central) - Mar 27, 2025
Minimal impact was observed on other lymphocytes including total T lymphocyte and natural killer cell counts. These findings support the further development of MK-6194 as a potential treatment for autoimmune disorders.
- || MK-6194 / Merck (MSD)
New P1 trial: A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014) (clinicaltrials.gov) - Feb 12, 2025
P1, N=37, Completed, Sponsor: Merck Sharp & Dohme LLC
- || MK-6194 / Merck (MSD)
Trial completion date, Trial primary completion date: Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) (clinicaltrials.gov) - Dec 27, 2024
P2, N=270, Recruiting, Sponsor: Merck Sharp & Dohme LLC
These findings support the further development of MK-6194 as a potential treatment for autoimmune disorders. Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Apr 2027
- || MK-6194 / Merck (MSD)
New P1 trial: MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013) (clinicaltrials.gov) - Oct 21, 2024
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme LLC
- || MK-6194 / Merck (MSD)
Enrollment closed: A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) (clinicaltrials.gov) - Sep 20, 2024
P2, N=165, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Apr 2027 Recruiting --> Active, not recruiting
- MK-6194 / Merck (MSD)
Design of a phase 2a, double-blind, placebo-controlled, global trial of MK-6194, a modified form of IL-2, in participants with non-segmental vitiligo. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2474;
P2
Recruiting --> Active, not recruiting This phase 2a trial will outline the efficacy, safety, and tolerability of MK-6194 compared with placebo in patients with non-segmental vitiligo.
- || MK-6194 / Merck (MSD)
Trial completion date, Trial primary completion date: A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) (clinicaltrials.gov) - Jun 4, 2024
P2, N=165, Recruiting, Sponsor: Merck Sharp & Dohme LLC
This phase 2a trial will outline the efficacy, safety, and tolerability of MK-6194 compared with placebo in patients with non-segmental vitiligo. Trial completion date: Apr 2026 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Jun 2025
- ||| MK-6194 / Merck (MSD)
Trial completion: Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) (clinicaltrials.gov) - Jun 3, 2024
P1, N=72, Completed, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Apr 2026 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Jun 2025 Active, not recruiting --> Completed
- ||| MK-6194 / Merck (MSD)
Trial completion: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Jun 2, 2024
P1, N=57, Completed, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- MK-6194 / Merck (MSD)
FIRST-IN-HUMAN SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS DATA WITH MK-6194, A MODIFIED FORM OF INTERLEUKIN-2, DESIGNED TO SELECTIVELY ACTIVATE REGULATORY T-CELLS (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1754;
The PK of MK-6194 was linear and dose-proportional, and observed Treg expansion was dose dependent without attenuation after repeat dosing. These results support further development of MK-6194 for the treatment of autoimmune disorders.
- || MK-6194 / Merck (MSD)
Enrollment change: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Jan 18, 2024
P1, N=57, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
These results support further development of MK-6194 for the treatment of autoimmune disorders. N=30 --> 57
- |||| MK-6194 / Merck (MSD)
Enrollment open: Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) (clinicaltrials.gov) - Jan 7, 2024
P2, N=270, Recruiting, Sponsor: Merck Sharp & Dohme LLC
N=30 --> 57 Not yet recruiting --> Recruiting
- || MK-6194 / Merck (MSD)
Enrollment closed: Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) (clinicaltrials.gov) - Dec 11, 2023
P1, N=72, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| MK-6194 / Merck (MSD)
Enrollment open, Phase classification: A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) (clinicaltrials.gov) - Dec 8, 2023
P2, N=165, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Phase classification: P2a --> P2
- ||||| MK-6194 / Merck (MSD)
New P2 trial: Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) (clinicaltrials.gov) - Dec 6, 2023
P2, N=270, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- || MK-6194 / Merck (MSD)
Enrollment closed, Trial completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Nov 21, 2023
P1, N=30, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting | Phase classification: P2a --> P2 Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> May 2024
- MK-6194 / Merck (MSD)
Phase classification: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Nov 13, 2023
P1, N=30, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> May 2024 Phase classification: P1b --> P1
- |||| MK-6194 / Merck (MSD)
New P2 trial, New P2a trial: A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) (clinicaltrials.gov) - Nov 1, 2023
P2a, N=165, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- || MK-6194 / Merck (MSD)
Enrollment open: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Oct 17, 2023
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P1b --> P1 Active, not recruiting --> Recruiting
- || MK-6194 / Merck (MSD)
Enrollment closed, Trial primary completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Oct 2, 2023
P1b, N=30, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Mar 2024
- | MK-6194 / Merck (MSD)
Trial primary completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Mar 2, 2023
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Mar 2024 Trial primary completion date: Mar 2024 --> Dec 2023
- | MK-6194 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Jan 6, 2023
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial primary completion date: Mar 2024 --> Dec 2023 Trial completion date: Jan 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Jan 2024
- ||| MK-6194 / Merck (MSD)
Enrollment open: Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) (clinicaltrials.gov) - Aug 11, 2022
P1, N=72, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Jan 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- ||| MK-6194 / Merck (MSD)
New P1 trial: Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) (clinicaltrials.gov) - Jul 7, 2022
P1, N=72, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | MK-6194 / Merck (MSD)
Trial primary completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Jun 14, 2022
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Trial primary completion date: May 2023 --> Jan 2023
- | MK-6194 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Mar 27, 2022
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: May 2023 --> Jan 2023 Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> May 2023
- | MK-6194 / Merck (MSD)
Trial completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Nov 18, 2021
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> May 2023 Trial completion date: Jan 2023 --> Nov 2023
- | MK-6194 / Merck (MSD)
Trial completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Oct 19, 2021
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jan 2023 --> Nov 2023 Trial completion date: Nov 2023 --> Jan 2023
- | MK-6194 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Sep 17, 2021
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Nov 2023 --> Jan 2023 Trial completion date: Oct 2022 --> Nov 2023 | Trial primary completion date: Oct 2022 --> Jan 2023
- || MK-6194 / Merck (MSD)
Enrollment open: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Sep 10, 2021
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Oct 2022 --> Nov 2023 | Trial primary completion date: Oct 2022 --> Jan 2023 Not yet recruiting --> Recruiting
- | MK-6194 / Merck (MSD)
Trial completion date: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Jul 1, 2021
P1b, N=30, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial completion date: Jun 2023 --> Oct 2022
- || MK-6194 / Merck (MSD)
New P1 trial: A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (clinicaltrials.gov) - Jun 11, 2021
P1b, N=30, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- PT101 / Merck (MSD)
[VIRTUAL] SAFETY, TOLERABILITY AND SELECTIVE EXPANSION OF REGULATORY T CELLS BY A SINGLE DOSE OF THE NOVEL IL-2 MUTEIN PT101 IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS () - May 21, 2021 - Abstract #EULAR2021EULAR_3147;
Marked expansion of both total Treg and CD25bright Treg cells was observed. High selectivity for Tregs was observed with no significant expansion of pro-inflammatory Tconv and NK cells even at the highest dose studied.
- PT101 / Merck (MSD)
[VIRTUAL] Generation of PT101, a highly selective IL-2 mutein for treatment of autoimmune diseases () - May 19, 2021 - Abstract #IMMUNOLOGY2021IMMUNOLOGY_2330;
There was no evidence of expansion of NK cells nor pro-inflammatory Tconv at any dose studied. Clinical trials in patients with ulcerative colitis and systemic lupus erythematosus are planned with PT101.
- PT101 / Merck (MSD)
[VIRTUAL] GENERATION OF PT101, A HIGHLY SELECTIVE IL-2 MUTEIN FOR TREATMENT OF AUTOIMMUNE DISEASES (Room 3) - Apr 6, 2021 - Abstract #EULAR2021EULAR_1261;
These Tregs have enhanced function and stability as seen by increase in expression of FOXP3 and CD25 in these cells. PT101 maintained selectivity in Phase 1 a clinical trial with no evidence of expansion of natural killer cells nor pro-inflammatory conventional T at any dose studied.
- PT101 / Pandion Therap
PT101: A Treg selective agonist IL-2 mutein therapy for autoimmunity (Board Number: P895) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_1473;
A 1-month toxicity study in cynomolgus monkeys indicated that PT101 was safe and well-tolerated at 300x the minimum efficacious dose whilst maintaining its Treg selectivity. PT101 is being evaluated in a randomized, placebo-controlled, double-blind, single ascending dose-escalation trial in healthy volunteers.